On January 5, 2018 NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, reported that the company will be hosting an Investor/Analyst Day on Tuesday, January 9th in San Francisco, California (Press release, NantKwest, JAN 5, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2325070 [SID1234522918]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NantKwest will be sharing with analysts and investors a review of the company’s activities in 2017 and provide a detailed overview for 2018. The record number of 15 INDs authorized in 2017 (aNK, haNK, Cryopreserved haNK and taNK) will be announced, detailing the multiple tumor types to be studied with combination chemo-radiation therapy and activators of adaptive immune system through adenovirus, yeast and super agonist IL-15 platforms. In addition, details will be presented regarding authorization in Europe to treat patients with glioblastoma and authorization by the FDA to initiate high-affinity natural killer (haNK) cell trials in cancer patients with HIV.

First in-human clinical data will be revealed including safety and early signs of clinical activity in patients receiving freshly cultured haNK, cryopreserved haNK and combinations of NK cells (aNK and haNK) with adenovirus, yeast, and super agonist IL-15 platforms. These studies form the basis for multiple Phase II and registration trials anticipated to be initiated in 2018.

At this event, senior management of NantKwest will provide a review of its ongoing R&D program, as well as provide an in-depth clinical trial roadmap for the company’s clinical programs for 2018 and the current status of the GMP manufacturing plants.

A webcast of the event will begin at 7:00 PM PT on Tuesday, January 9, 2018 and is expected to conclude at 9:00 PT. A link to the live webcast can be accessed by visiting the Investors page of the company’s website. In addition, a replay of the event will be posted on the website after the event and will be available for 30 days following the event.

On January 5, 2018 Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, reported that it is changing its name to Avid Bioservices, Inc. as part of its transition to a dedicated contract development and manufacturing organization (CDMO) (Press release, Peregrine Pharmaceuticals, JAN 5, 2018, View Source [SID1234522924]). In addition to the name change, the company is also adopting the new NASDAQ ticker symbol "CDMO" (NASDAQ:CDMO). The name and ticker symbol changes will both be effective as of market open on Monday, January 8, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As our organization transitions to a pure play CDMO, we believe it is appropriate to take advantage of the brand recognition that has been built within this highly specialized marketplace and to change the company’s name and conduct all future operations as Avid Bioservices," said Roger Lias, Ph.D., president and chief executive officer. "Over the past 15 years, Avid has established a reputation for CDMO excellence built on biologics manufacturing expertise and a track record of consistently meeting and exceeding the needs of its clients. This level of quality is highlighted by Avid’s receipt of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. We look forward to continuing to build the Avid brand as we work to grow and diversify our CDMO business by providing our clients with the most sophisticated and highest-quality development and manufacturing services."

Effective at market open on Monday, January 8, 2018, trading for Avid Bioservices will begin under the symbol "CDMO" (NASDAQ:CDMO). At the same time, the company’s preferred stock will begin trading under the symbol "CDMOP" (NASDAQ:CDMOP). The company’s common stock and preferred stock will continue to trade under the ticker symbols "PPHM" and "PPHMP", respectively, until market close on Friday, January 5, 2018. The corporate name change to Avid Bioservices does not affect the rights of the company’s stockholders and no action is required by stockholders with respect to the name change. The company’s common stock has been assigned a new CUSIP number of 05368M 106 and the company’s preferred stock has been assigned a new CUSIP number of 05368M 205 in connection with the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

On January 5, 2018 Spectrum Pharmaceuticals presented Presentation materials dated January 8, 2018 (Presentation, Spectrum Pharmaceuticals, JAN 5, 2018, View Source [SID1234523078]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 5, 2018 Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA) constructs, reported that the company is scheduled to present at the 10th Annual Biotech Showcase conference held January 8-10, 2018 in San Francisco (Press release, Exicure, JAN 5, 2018, View Source;p=RssLanding&cat=news&id=2325180 [SID1234523073]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company overview on Tuesday, January 9th at 10:15 a.m. Pacific Time at the Hilton Union Square in San Francisco.

A live webcast of the presentation will be available on the Events & Presentations section of Exicure’s website and will also be archived following the presentation.

On January 5, 2018 AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), reported that it will present at Biotech Showcase, January 8-10, 2018 at the Hilton San Francisco Union Square (Press release, BioTime, JAN 5, 2018, View Source;p=RssLanding&cat=news&id=2325217 [SID1234522928]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael D. West, Ph.D., Chief Executive Officer, will present at the conference as follows:

Date: Tuesday, January 9
Time: 2:30 PM PST
Track: Yosemite-B (Ballroom Level)
Venue: Hilton San Francisco Union Square, 333 O’Farrell Street

According to the event organizers, Biotech Showcase features more than 3,500 decision makers from 2,100 life sciences companies in a variety of plenary sessions, fireside chats, and panels. This year’s event is expected to draw over 900 investors from 50-plus countries, in anticipation of 400-plus public and private company presentations.

A copy of Dr. West’s presentation will be available on the AgeX website.